HERSHEY, Pa. and ROCKVILLE, Md., May 4, 2015 (GLOBE NEWSWIRE) -- Immunomic Therapeutics, Inc. (ITI), a privately-held biotechnology company developing vaccines based on its proprietary LAMP technology, today announces it has appointed Eric Winzer as its new chief financial officer beginning May 4, 2015.
"Eric's extensive experience in a variety of public and private companies will serve Immunomic Therapeutics well as we continue to evolve our business," said William Hearl, Ph.D., CEO of ITI. "His understanding of the particular needs of the life sciences industry will help guide us through many of our anticipated upcoming milestones and we are thrilled to welcome him to ITI."
A 30-year veteran of live sciences companies, Mr. Winzer has addressed a wide array of financial issues from raising capital, financial reporting, investor relations, banking, taxation, mergers and acquisitions to financial planning and analysis, and accounting operations. Most recently, he was CFO of OpGen where he was responsible for all financial functions at the company. Prior to joining OpGen, Mr. Winzer served as executive vice president and CFO for Avalon Pharmaceuticals, Inc., a biotechnology company developing targeted therapeutics for oncology. Prior to Avalon, Eric was with Life Technologies Corporation (formerly Invitrogen Corporation), a provider of life science technologies for disease research and drug discovery, where he served as senior VP and CFO, executive sponsor for Life's ERP implementation, and as VP of finance. Currently, Mr. Winzer also serves as director and audit committee chair at NUO Therapeutics. He received his BA in economics and business administration from McDaniel College and an MBA from Mount Saint Mary's University.
About Immunomic Therapeutics, Inc.
Immunomic Therapeutics, Inc. is a Hershey, PA-based, privately held, clinical stage biotechnology company developing vaccines based on the LAMP technology platform, which was exclusively licensed from Johns Hopkins University. The LAMP-vax vaccine platform aims to increase the immune response to nucleic acid vaccines and simplify vaccine design and delivery for safer, more cost-effective therapies. ITI's LAMP constructs have been validated in human clinical trials for cancer and have been studied in areas including allergy and infectious disease, while internally ITI is focused on developing allergy therapies. Currently, the company is pursuing three main allergy programs:
ASP 4070 (Formerly known as JRC-LAMP-Vax) - Japanese Red Cedar Vaccine - An innovative potential solution for the over 35 million sufferers of Japanese red cedar pollinosis - Phase I, currently partnered with Astellas Pharma;
An analogous vaccine formulation will be developed as a vaccine to treat Mountain Cedar in the US.
ARA-LAMP-Vax Peanut Allergy Vaccine - A therapeutic vaccine in development, with a goal of mitigating peanut allergy - Beginning Phase I in late 2015/early 2016;
Multi Allergen Vaccines (Product Concepts) - Allergy vaccine formulation concepts that would aim to address the major categories of allergies of concern worldwide - Under study & development.
For more information about ITI and LAMP Technology, please visit www.immunomix.com.